Ocumetra's mEYE Suite: A Bridge to Myopia Management, Not a Biometer Replacement

A biometer costs upwards of £20,000. A ten-minute conversation with a worried parent costs you nothing but chair time you don't have. Myopia management has always demanded both, and that's exactly why so many independents have watched treatment programmes stall before they start. A piece of software built by two of the field's own researchers is now taking a run at both problems at once.

The hardware barrier nobody talks about

Gold-standard myopia management means tracking axial length: the physical growth of the eyeball, measured front to back. It's the single most reliable way to know whether a treatment is working. It's also the reason so many independents quietly avoid offering full myopia control at all. Specialist biometers run into five figures, and a machine that sits idle for most of the week doesn't survive a sensible P&L review.

Corporate multiples don't have that problem. Central buying power and shared equipment budgets mean an OCT-linked biometer is a rounding error across a hundred stores. For a single-site independent, it's a decision that keeps the owner up at night.

Ocumetra, an Irish digital health company founded in 2020 by myopia researchers Professor Ian Flitcroft and Professor James Loughman, has built a software platform called the mEYE Suite that goes some way to solving that problem — not by replacing the biometer, but by giving practices a way to start without one. It's worth understanding exactly what it does and doesn't do, because the independence angle here is real, but it comes with a caveat worth reading before you get to the pricing conversation.

What the mEYE Suite actually does

The platform is web-based, so there's nothing to install locally. It's built around three connected modules, and each one is solving a different part of the myopia consultation.

mEYE Gauge — an estimate, not a replacement

This is the module that matters most for the capital question, and it's also the one to be precise about. mEYE Gauge is a machine-learning model, trained on more than a million patient records, that estimates axial length from data most practices already capture: age, gender, refraction and keratometry. No specialist hardware required to generate that estimate.

What it isn't is a substitute for a physical biometer. Ocumetra itself positions mEYE Gauge as a way in — a tool that lets a practice start tracking myopia risk and having the treatment conversation before it has invested in dedicated equipment, not a permanent alternative to owning one. An actual optical biometer takes a direct physical measurement of the eye. It's repeatable to a degree software estimation can't match, and it's still the instrument you want for picking up the small, incremental changes that tell you whether a treatment dose needs adjusting. For a practice fine-tuning an existing myopia programme, that precision matters.

Where mEYE Gauge earns its place is at the start of that journey, not the end of it: it removes the reason not to begin.

mEYE Guide — the conversation, automated

Parents don't glaze over because they don't care. They glaze over because dioptres mean nothing to them. mEYE Guide replaces the verbal explanation with interactive vision simulations and infographics that show, visually, how a child's prescription compares to their peers and what happens if nothing changes. Ocumetra's own clinical user data puts the time saved at an average of 8.2 minutes per consultation — chair time an independent can either give back to the day or use to see another patient.

mEYE Score — proof the treatment is working

Compliance drops off when families stop believing the specialist lenses or atropine drops are doing anything. mEYE Score models treatment benefit using metrics built specifically for the consultation room — Treatment Efficacy Index, Cumulative Refractive Benefit, Cumulative Axial Length Modification — and covers the major branded options in the market, including CooperVision's MiSight, Menicon's Bloom and Hoya's MiYOSMART. It gives the practice something concrete to show a parent at the six-month review, rather than asking them to take it on trust.

The numbers Ocumetra is publishing

According to Ocumetra's Clinical User Report, practices that integrate the platform into their existing workflow report the following:

These are figures from the vendor's own reporting, not an independent clinical trial, and any practice considering the platform should ask Ocumetra directly for the methodology behind them before quoting these numbers to patients or investors. That's not a knock on the product — it's just how due diligence works, and it's worth doing before any equipment or software decision, however good the sales conversation feels.

Where it sits in your existing setup

The platform is designed to sit behind your current tech stack rather than becoming another disconnected browser tab. It integrates with Topcon Healthcare's Harmony platform, so diagnostic data can sync through automatically, and connects to cloud-hosted practice management systems via Ocuco, which also holds an equity stake in the business. For a practice already running Ocuco PMS or Topcon diagnostics, that's a genuinely lower-friction route in than most add-on clinical software manages. For a practice running neither, it's a question worth asking early: how much of the "no specialist hardware" pitch depends on hardware you don't currently have?

On compliance, Ocumetra states the platform meets GDPR, HIPAA and ISO/IEC 27001 requirements and offers a multilingual interface — relevant if your patient base isn't English-first, and worth confirming directly rather than assuming it covers every regulatory box your practice needs ticked.

The independence angle

Myopia management is one of the clearest growth opportunities independent practice has in front of it right now — recurring reviews, ongoing treatment relationships, genuine clinical value beyond a sight test. The thing that's kept many independents out of it isn't clinical willingness. It's capital, and specifically the up-front cost of biometry equipment that a multiple can absorb across a hundred sites and a single practice can't.

What mEYE Gauge changes is the order you're allowed to do things in. Instead of "buy a £20,000 biometer, then start offering myopia management," an independent can start offering it on estimated data, build the patient volume and the revenue case, and buy the physical instrument once the numbers justify it. That's a genuinely different capital decision, and it's one a multiple never had to make in the first place because the equipment budget was never the constraint.

It doesn't mean the biometer becomes optional forever. If you're running a serious myopia control programme, you'll want one eventually, for the same reason you'd eventually want an OCT rather than relying on fundus photography alone: better data makes better clinical decisions. Treat this as a bridge, not a bypass, and it's a genuinely useful one. Treat it as a permanent substitute and you're making a clinical trade-off you should be making with your eyes open, not because a sales conversation implied you wouldn't need to.

Ocumetra's own site has the full detail on the mEYE Suite, including case studies and pricing conversations: ocumetra.com.

If you're weighing up equipment and software investments as you grow your practice, this is exactly the kind of decision worth talking through properly.

Talk to Grow Independent